125 related articles for article (PubMed ID: 21772095)
1. [A retrospective study of high-dose toremifene treatment for patients with aromatase inhibitor refractory advanced or metastatic hormone receptor-positive breast cancer].
Koyama H; Iesato A; Fukushima Y; Okada T; Watanabe T; Harada M; Ito T; Maeno K; Mochizuki Y; Ito K; Amano J
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1123-6. PubMed ID: 21772095
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of high-dose toremifene as a second-line hormone therapy in patients with advanced or metastatic breast cancer resistant to aromatase inhibitor].
Kubota O; Onuki Y; Uchiyama T; Oishi K; Takeda M
Gan To Kagaku Ryoho; 2012 May; 39(5):753-7. PubMed ID: 22584326
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors].
Ohtake T; Yasuda M; Watanabe K; Ito T; Ito J; Miyamoto K; Yoshida S; Abe N; Ishigame T; Ishii M; Kimijima I; Takenoshita S
Gan To Kagaku Ryoho; 2009 Sep; 36(9):1459-63. PubMed ID: 19755813
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of treatment with high-dose toremifene in patients with metastatic breast cancer resistant to aromatase inhibitor treatment].
Niikura N; Kimura M; Kobayashi Y; Asahara F; Hayashi K; Shibata S; Shintoku J
Gan To Kagaku Ryoho; 2009 Jun; 36(6):1013-6. PubMed ID: 19542727
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of high-dose toremifene therapy in postmenopausal patients with metastatic breast cancer resistant to aromatase inhibitors:a retrospective, single-institution study.
Ishizuna K; Ninomiya J; Ogawa T; Tsuji E; Kojima M; Kawashima M; Nozaki M; Yamagishi H; Ueda Y; Oya M
Gan To Kagaku Ryoho; 2014 Aug; 41(8):965-70. PubMed ID: 25132027
[TBL] [Abstract][Full Text] [Related]
6. [A study of the efficacy of high-dose toremifene in advanced and recurrent breast cancer].
Tokura H; Fujisaki M; Takahashi T; Takigawa Y; Onouchi S; Matsuda K; Hirata A
Gan To Kagaku Ryoho; 2012 Jul; 39(7):1071-3. PubMed ID: 22790041
[TBL] [Abstract][Full Text] [Related]
7. [Experience of high-dose toremifene treatment for postmenopausal women with metastatic breast cancer].
Yamamoto Y; Kawazoe T; Iwase H
Gan To Kagaku Ryoho; 2005 Oct; 32(10):1415-9. PubMed ID: 16227740
[TBL] [Abstract][Full Text] [Related]
8. Phase II clinical trial of high-dose toremifene as primary hormone therapy in aromatase inhibitor-resistant breast cancer.
Ogata H; Okamoto Y; Arima Y; Fukushima H; Takeyama H; Yamashita A; Kinoshita M; Suzuki N; Sawada T; Koshida Y; Matsui A; Tachibana A; Nakayama H; Oishi Y; Nogi H; Uchida K
Gan To Kagaku Ryoho; 2013 Jun; 40(6):749-53. PubMed ID: 23863651
[TBL] [Abstract][Full Text] [Related]
9. [The combined effect of Paclitaxel and toremifene therapy for estrogen receptor positive and aromatase inhibitor resistant metastatic breast cancer].
Sakurai K; Enomoto K; Amano S
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2246-8. PubMed ID: 21224536
[TBL] [Abstract][Full Text] [Related]
10. The clinical benefit of high-dose toremifene for metastatic breast cancer.
Koike K; Edo M; Higaki M; Kitahara K; Satou S; Noshiro H
Gan To Kagaku Ryoho; 2013 Jul; 40(7):877-80. PubMed ID: 23863727
[TBL] [Abstract][Full Text] [Related]
11. [Indoleamine 2,3-dioxygenase activity during toremifene therapy for aromatase inhibitor-resistant metastatic breast cancer].
Sakurai K; Fujisaki S; Nagashima S; Maeda T; Tomita R; Suzuki S; Hara Y; Hirano T; Enomoto K; Amano S
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1286-8. PubMed ID: 25335719
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
13. [A case of aromatase inhibitor-tolerant metastatic breast cancer revealing complete remission with high-dose toremifene therapy].
Kurozumi S; Takeo T; Ikeda F; Horiguchi J; Takeyoshi I; Ito H
Gan To Kagaku Ryoho; 2011 Jan; 38(1):93-6. PubMed ID: 21368465
[TBL] [Abstract][Full Text] [Related]
14. High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review.
Mahtani RL; Stein A; Vogel CL
Clin Ther; 2009; 31 Pt 2():2371-8. PubMed ID: 20110046
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
16. Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor.
Yamamoto Y; Masuda N; Ohtake T; Yamashita H; Saji S; Kimijima I; Kasahara Y; Ishikawa T; Sawaki M; Hozumi Y; Iwase H
Breast Cancer; 2010 Oct; 17(4):254-60. PubMed ID: 19685269
[TBL] [Abstract][Full Text] [Related]
17. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.
Buzdar AU; Vergote I; Sainsbury R
Breast J; 2004; 10(3):211-7. PubMed ID: 15125747
[TBL] [Abstract][Full Text] [Related]
18. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
[TBL] [Abstract][Full Text] [Related]
19. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
[TBL] [Abstract][Full Text] [Related]
20. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
